Edgestream Partners L.P. Purchases 74,427 Shares of Sarepta Therapeutics, Inc. $SRPT

Edgestream Partners L.P. lifted its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 870.3% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,979 shares of the biotechnology company’s stock after acquiring an additional 74,427 shares during the period. Edgestream Partners L.P. owned approximately 0.08% of Sarepta Therapeutics worth $1,419,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SRPT. Inspire Investing LLC acquired a new stake in shares of Sarepta Therapeutics in the 1st quarter valued at $967,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Sarepta Therapeutics by 54.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 463,342 shares of the biotechnology company’s stock worth $29,570,000 after buying an additional 164,041 shares during the last quarter. Tempus Wealth Planning LLC lifted its position in shares of Sarepta Therapeutics by 475.8% during the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company’s stock worth $353,000 after buying an additional 17,070 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in Sarepta Therapeutics by 21.8% in the second quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company’s stock valued at $14,842,000 after buying an additional 155,358 shares in the last quarter. Finally, Trexquant Investment LP bought a new position in Sarepta Therapeutics in the first quarter valued at about $11,997,000. 86.68% of the stock is owned by institutional investors.

Analyst Ratings Changes

SRPT has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Sarepta Therapeutics in a report on Monday, November 24th. Piper Sandler upped their price objective on shares of Sarepta Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a research report on Thursday, October 30th. Wall Street Zen lowered shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Guggenheim decreased their target price on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. Finally, HC Wainwright reiterated a “sell” rating on shares of Sarepta Therapeutics in a research note on Monday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and six have given a Sell rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Hold” and an average target price of $33.75.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $22.26 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.95 and a debt-to-equity ratio of 0.78. Sarepta Therapeutics, Inc. has a twelve month low of $10.41 and a twelve month high of $131.31. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -7.40 and a beta of 0.54. The company’s fifty day moving average is $20.79 and its 200 day moving average is $21.70.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 4.85% and a negative net margin of 11.25%.The company had revenue of $399.36 million for the quarter, compared to the consensus estimate of $331.51 million. During the same period in the prior year, the business earned $0.62 earnings per share. The firm’s revenue for the quarter was down 14.5% on a year-over-year basis. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.